| Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer J Heo, T Reid, L Ruo, CJ Breitbach, S Rose, M Bloomston, M Cho, HY Lim, ... Nature medicine 19 (3), 329-336, 2013 | 889 | 2013 |
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study PJ Johnson, S Qin, JW Park, RTP Poon, JL Raoul, PA Philip, CH Hsu, ... Journal of clinical oncology 31 (28), 3517-3524, 2013 | 871 | 2013 |
| All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study M Manns, S Pol, IM Jacobson, P Marcellin, SC Gordon, CY Peng, ... The Lancet 384 (9954), 1597-1605, 2014 | 456 | 2014 |
| Endoscopic sphincterotomy plus large-balloon dilation versus endoscopic sphincterotomy for removal of bile-duct stones JH Heo, DH Kang, HJ Jung, DS Kwon, JK An, BS Kim, KD Suh, SY Lee, ... Gastrointestinal endoscopy 66 (4), 720-726, 2007 | 348 | 2007 |
| Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans CJ Breitbach, R Arulanandam, N De Silva, SH Thorne, R Patt, ... Cancer research 73 (4), 1265-1275, 2013 | 304 | 2013 |
| Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage YS Seo, SY Park, MY Kim, JH Kim, JY Park, HJ Yim, BK Jang, HS Kim, ... Hepatology 60 (3), 954-963, 2014 | 290 | 2014 |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label … S Qin, M Chen, AL Cheng, AO Kaseb, M Kudo, HC Lee, AC Yopp, J Zhou, ... The Lancet 402 (10415), 1835-1847, 2023 | 234 | 2023 |
| Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind … M Kudo, AL Cheng, JW Park, JH Park, PC Liang, H Hidaka, N Izumi, ... The lancet Gastroenterology & hepatology 3 (1), 37-46, 2018 | 194 | 2018 |
| Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy J Heo, CJ Breitbach, A Moon, CW Kim, R Patt, MK Kim, YK Lee, SY Oh, ... Molecular Therapy 19 (6), 1170-1179, 2011 | 166 | 2011 |
| Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs JH Lee, HK Park, J Heo, TO Kim, GH Kim, DH Kang, G Am Song, M Cho, ... Journal of Korean medical science 23 (3), 521, 2008 | 156 | 2008 |
| Efficacy and safety of bepirovirsen in chronic hepatitis B infection MF Yuen, SG Lim, R Plesniak, K Tsuji, HLA Janssen, C Pojoga, A Gadano, ... New England Journal of Medicine 387 (21), 1957-1968, 2022 | 152 | 2022 |
| Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial MF Yuen, J Heo, JW Jang, JH Yoon, YO Kweon, SJ Park, Y Tami, S You, ... Nature medicine 27 (10), 1725-1734, 2021 | 126 | 2021 |
| Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial MS Sulkowski, T Asselah, J Lalezari, P Ferenci, H Fainboim, B Leggett, ... Hepatology 57 (6), 2143-2154, 2013 | 122 | 2013 |
| Endoscopic bilateral metal stent placement for advanced hilar cholangiocarcinoma: a pilot study of a newly designed Y stent JH Lee, DH Kang, JY Kim, SM Lee, DH Kim, CW Park, HS Cho, GH Kim, ... Gastrointestinal Endoscopy 66 (2), 364-369, 2007 | 122 | 2007 |
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with … R Lencioni, M Kudo, J Erinjeri, S Qin, Z Ren, S Chan, Y Arai, J Heo, A Mai, ... Journal of Clinical Oncology 42 (3_suppl), LBA432-LBA432, 2024 | 121 | 2024 |
| RNA interference therapy with ARC‐520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection MF Yuen, I Schiefke, JH Yoon, SH Ahn, J Heo, JH Kim, H Lik Yuen Chan, ... Hepatology 72 (1), 19-31, 2020 | 121 | 2020 |
| Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb … M Moehler, J Heo, HC Lee, WY Tak, Y Chao, SW Paik, HJ Yim, KS Byun, ... Oncoimmunology 8 (8), 1615817, 2019 | 120 | 2019 |
| Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans MK Kim, CJ Breitbach, A Moon, J Heo, YK Lee, M Cho, JW Lee, SG Kim, ... Science translational medicine 5 (185), 185ra63-185ra63, 2013 | 119 | 2013 |
| A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable … HY Lim, J Heo, HJ Choi, CY Lin, JH Yoon, C Hsu, KM Rau, RTP Poon, ... Clinical Cancer Research 20 (23), 5976-5985, 2014 | 117 | 2014 |
| Is it possible to differentiate gastric GISTs from gastric leiomyomas by EUS? GH Kim, S Kim, DH Kim, DH Kim, CW Choi, J Heo, G Am Song World Journal of Gastroenterology: WJG 15 (27), 3376, 2009 | 117 | 2009 |
Ki Tae YoonAssociate Professor, Liver Center, Pusan National University Yangsan HosptialEmail verificata su pusan.ac.kr
